Gafanzer Belge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1731324/publications.pdf

Version: 2024-02-01

81	2,774	186265	197818
papers	citations	28 h-index	49 g-index

86	86	86	2598
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1. World Journal of Urology, 2022, 40, 317-326.	2.2	8
2	Serum Levels of MicroRNA-371a-3p (M371) Can Predict Absence or Presence of Vital Disease in Residual Masses After Chemotherapy of Metastatic Seminoma. Frontiers in Oncology, 2022, 12, .	2.8	7
3	High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours. Urologia Internationalis, 2021, 105, 21-26.	1.3	6
4	Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin. Journal of Cancer Research and Clinical Oncology, 2021, 147, 435-443.	2.5	18
5	A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis. Clinical Genitourinary Cancer, 2021, 19, 469-479.	1.9	19
6	Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. European Urology, 2021, 80, 456-466.	1.9	60
7	Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma. In Vivo, 2020, 34, 163-168.	1.3	29
8	Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nature Reviews Urology, 2020, 17, 201-213.	3.8	67
9	Lung Surfactant Accelerates Skin Wound Healing: A Translational Study with a Randomized Clinical Phase I Study. Scientific Reports, 2020, 10, 2581.	3.3	15
10	Non-Coding microRNAs as Novel Potential Tumor Markers in Testicular Cancer. Cancers, 2020, 12, 749.	3.7	44
11	Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor. Oncotarget, 2020, 11, 1462-1473.	1.8	19
12	Expression of miRNAâ€371aâ€3p in seminal plasma and ejaculate is associated with sperm concentration. Andrology, 2019, 7, 469-474.	3.5	31
13	Matrix Metalloproteinase-3 is Key Effector of TNF-Î±-Induced Collagen Degradation in Skin. International Journal of Molecular Sciences, 2019, 20, 5234.	4.1	33
14	Microfluidic oxygen sensor system as a tool to monitor the metabolism of mammalian cells. Sensors and Actuators B: Chemical, 2019, 289, 24-31.	7.8	13
15	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. Journal of Clinical Oncology, 2019, 37, 1412-1423.	1.6	246
16	Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. Cells, 2019, 8, 1637.	4.1	73
17	Mechanical and migratory properties of normal, scar, and Dupuytren's fibroblasts. Journal of Molecular Recognition, 2018, 31, e2719.	2.1	16
18	The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1. Urologia Internationalis, 2018, 100, 470-475.	1.3	60

#	Article	IF	Citations
19	Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2383-2392.	2.5	35
20	Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. European Urology, 2017, 71, 213-220.	1.9	161
21	Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series. Urologia Internationalis, 2017, 99, 98-103.	1.3	36
22	The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines. Anticancer Research, 2017, 37, 6341-6345.	1.1	23
23	Generation and Characterization of Vascular Smooth Muscle Cell Lines Derived from a Patient with a Bicuspid Aortic Valve. Cells, 2016, 5, 19.	4.1	3
24	MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid. Urologia Internationalis, 2016, 97, 76-83.	1.3	44
25	Expression of microRNAs of C19MC in Different Histological Types of Testicular Germ Cell Tumour. Cancer Genomics and Proteomics, 2016, 13, 281-9.	2.0	24
26	HMGA2 expression distinguishes between different types of postpubertal testicular germ cell tumour. Journal of Pathology: Clinical Research, 2015, 1, 239-251.	3.0	5
27	Micro<scp>RNA</scp> miRâ€371aâ€3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker. Andrology, 2015, 3, 78-84.	3.5	79
28	Is measuring serum levels of microRNA miR-371a-3p superior to the classical biomarkers of testicular germ cell tumors?. Journal of Clinical Oncology, 2015, 33, 376-376.	1.6	2
29	Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors?. Anticancer Research, 2015, 35, 117-21.	1.1	17
30	Cell cultures in uterine leiomyomas: Rapid disappearance of cells carrying MED12 mutations. Genes Chromosomes and Cancer, 2014, 53, 317-323.	2.8	27
31	Targeted serum miRNA (TSmiR) test for diagnosis and followâ€up of (testicular) germ cell cancer patients: A proof ofÂprinciple. Molecular Oncology, 2013, 7, 1083-1092.	4.6	142
32	Locally Different Endothelial Nitric Oxide Synthase Protein Levels in Ascending Aortic Aneurysms of Bicuspid and Tricuspid Aortic Valve. Cardiology Research and Practice, 2012, 2012, 1-8.	1.1	35
33	MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. British Journal of Cancer, 2012, 107, 1754-1760.	6.4	148
34	Serum Levels of MicroRNAs miR-371-3: A Novel Class of Serum Biomarkers for Testicular Germ Cell Tumors?. European Urology, 2012, 61, 1068-1069.	1.9	100
35	Detection of PAX8â€“PPARG fusion transcripts in archival thyroid carcinoma samples by conventional RTâ€PCR. Genes Chromosomes and Cancer, 2012, 51, 402-408.	2.8	12
36	Interphase fluorescence in situ hybridization analysis detects a much higher rate of thyroid tumors with clonal cytogenetic deviations of the main cytogenetic subgroups than conventional cytogenetics. Cancer Genetics, 2011, 204, 366-374.	0.4	8

#	Article	IF	Citations
37	On the prevalence of the PAX8-PPARG fusion resulting from the chromosomal translocation t(2;3)(q13;p25) in adenomas of the thyroid. Cancer Genetics, 2011, 204, 334-339.	0.4	14
38	HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications. Anticancer Research, 2011, 31, 753-61.	1.1	28
39	Upregulation of the high mobility group AT-hook 2 gene in acute aortic dissection is potentially associated with endothelial-mesenchymal transition. Histology and Histopathology, 2011, 26, 1029-37.	0.7	10
40	Inhibition of caspase-3 differentially affects vascular smooth muscle cell apoptosis in the concave versus convex aortic sites in ascending aneurysms with a bicuspid aortic valve. Annals of Anatomy, 2010, 192, 145-150.	1.9	30
41	Loss of let-7 binding sites resulting from truncations of the 3â€² untranslated region of HMGA2 mRNA in uterine leiomyomas. Cancer Genetics and Cytogenetics, 2010, 196, 119-123.	1.0	29
42	Cell culture and senescence in uterine fibroids. Cancer Genetics and Cytogenetics, 2010, 202, 53-57.	1.0	13
43	The Two Stem Cell MicroRNA Gene Clusters C19MC and miR-371-3 Are Activated by Specific Chromosomal Rearrangements in a Subgroup of Thyroid Adenomas. PLoS ONE, 2010, 5, e9485.	2.5	95
44	6p21 rearrangements in uterine leiomyomas targeting HMGA1. Cancer Genetics and Cytogenetics, 2010, 203, 247-252.	1.0	34
45	Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes and Cancer, 2009, 48, 171-178.	2.8	55
46	Upregulation of HMGA2 in thyroid carcinomas: A novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes and Cancer, 2008, 47, 56-63.	2.8	75
47	A closer look at Warthin tumors and the t(11;19). Cancer Genetics and Cytogenetics, 2008, 180, 135-139.	1.0	71
48	A domain of the thyroid adenoma associated gene (THADA) conserved in vertebrates becomes destroyed by chromosomal rearrangements observed in thyroid adenomas. Gene, 2007, 403, 110-117.	2.2	29
49	Evidence for a 3p25 Breakpoint Hot Spot Region in Thyroid Tumors of Follicular Origin. Thyroid, 2006, 16, 1091-1096.	4.5	23
50	A Human Corneal Equivalent Constructed from SV40-immortalised Corneal Cell Lines. ATLA Alternatives To Laboratory Animals, 2005, 33, 37-45.	1.0	49
51	Does conventional cytogenetics detect the real frequency of 19q13 aberrations in benign thyroid lesions? A survey of 38 cases. Cancer Genetics and Cytogenetics, 2003, 146, 70-72.	1.0	3
52	Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene, 2003, 22, 6111-6114.	5.9	65
53	A 3.4-kbp transcript of ZNF331 is solely expressed in follicular thyroid adenomas. Cytogenetic and Genome Research, 2003, 101, 113-117.	1.1	16
54	An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591. British Journal of Haematology, 2002, 119, 640-646.	2.5	20

#	Article	IF	Citations
55	Cytogenetic tetraclonality in a rare spindle cell variant of an anaplastic carcinoma of the thyroid. Cancer Genetics and Cytogenetics, 2001, 125, 163-166.	1.0	4
56	Delineation of a 150-kb breakpoint cluster in benign thyroid tumors with 19q13.4 aberrations. Cytogenetic and Genome Research, 2001, 93, 48-51.	1.1	17
57	Molecular cytogenetic investigations define a subgroup of thyroid adenomas with 2p21 breakpoints clustered to a region of less than 450 kb. Cytogenetic and Genome Research, 2001, 95, 189-191.	1.1	9
58	Detection of Epstein-Barr Virus in Hodgkin-Reed-Sternberg Cells. American Journal of Pathology, 2000, 156, 209-216.	3.8	38
59	Structural Abnormalities of Chromosome 2 in Benign Thyroid Tumors. Cancer Genetics and Cytogenetics, 1999, 114, 75-77.	1.0	22
60	Involvement of theHMGI(Y) gene in a microfollicular adenoma of the thyroid. Genes Chromosomes and Cancer, 1999, 24, 286-289.	2.8	12
61	A KRAB zinc finger protein gene is the potential target of 19q13 translocation in benign thyroid tumors. , 1999, 26, 229-236.		15
62	A KRAB zinc finger protein gene is the potential target of 19q13 translocation in benign thyroid tumors. Genes Chromosomes and Cancer, 1999, 26, 229-236.	2.8	3
63	A KRAB zinc finger protein gene is the potential target of 19q13 translocation in benign thyroid tumors. Genes Chromosomes and Cancer, 1999, 26, 229-36.	2.8	5
64	Involvement of the HMGIY gene in a microfollicular adenoma of the thyroid. Genes Chromosomes and Cancer, 1999, 24, 286-289.	2.8	6
65	Cytogenetic investigations of 340 thyroid hyperplasias and adenomas revealing correlations between cytogenetic findings and histology. Cancer Genetics and Cytogenetics, 1998, 101, 42-48.	1.0	78
66	Follicular thyroid carcinoma: Chromosome analysis of 19 cases. , 1998, 21, 250-255.		34
67	Follicular thyroid carcinoma: Chromosome analysis of 19 cases. Genes Chromosomes and Cancer, 1998, 21, 250-255.	2.8	1
68	Follicular thyroid carcinoma: chromosome analysis of 19 cases. Genes Chromosomes and Cancer, 1998, 21, 250-5.	2.8	4
69	Integration of Epstein-Barr virus in Burkitt's lymphoma cells leads to a region of enhanced chromosome instability. Annals of Oncology, 1997, 8, S131-S135.	1.2	25
70	Breakpoints of 19q13 translocations of benign thyroid tumors map within a 400 kilobase region. Genes Chromosomes and Cancer, 1997, 20, 201-203.	2.8	10
71	Breakpoints of 19q13 translocations of benign thyroid tumors map within a 400 kilobase region. Genes Chromosomes and Cancer, 1997, 20, 201-3.	2.8	2
72	Mapping of the translocation breakpoints of primary pleomorphic adenomas and lipomas within a common region of chromosome 12. Cancer Genetics and Cytogenetics, 1996, 86, 39-45.	1.0	20

#	Article	IF	Citations
73	Deletions of the short arm of chromosome 2 characterize a new cytogenetic subgroup of benign thyroid tumors. , 1996, 16, 149-151.		7
74	FISH analyses of a newly established thyroid tumor cell line showing a t(1;19)(p35 or p36.1;q13) reveal that the breakpoint lies between 19q13.3â€“13.4 and 19q13.4. Cytogenetic and Genome Research, 1995, 69, 220-222.	1.1	7
75	A characteristic sequence of trisomies starting with trisomy 7 in benign thyroid tumors. Human Genetics, 1994, 94, 198-202.	3.8	41
76	Cytogenetic biclonality corresponding to multiphasic differentiation in an atypical thyroid adenoma. Cancer Genetics and Cytogenetics, 1994, 78, 102-104.	1.0	8
77	Expression of SV40 T-antigen in lipoma cells with a chromosomal translocation T(3;12) is not sufficient for direct immortalization. Cell Biology International Reports, 1992, 16, 339-347.	0.6	15
78	Aberrations of chromosome 19. Cancer Genetics and Cytogenetics, 1992, 60, 23-26.	1.0	29
79	Deletion of part of the long arm of chromosome 13 as the only karyotypic aberration in a follicular thyroid adenoma. Cancer Genetics and Cytogenetics, 1991, 56, 277-280.	1.0	16
80	Transformation of human benign tumor cells â€" Suitable tool for investigations at the molecular level?. Cancer Genetics and Cytogenetics, 1991, 52, 258-259.	1.0	0
81	Cytogenetic investigations on a cell line derived from a carcinoma arising in a salivary gland pleomorphic adenoma. Cancer Genetics and Cytogenetics, 1990, 44, 253-262.	1.0	18